U.S. HSV Testing Market (2025 - 2033) Size, Share & Trends Analysis By Type (HSV-1/HSV-2 Combines, HSV-1, HSV-2), By Test Type, By Sample Type (Blood, Swabs, Cerebrospinal Fluid), By End Use, By Region, And Segment Forecasts

Table of Contents

Chapter 1. U.S. HSV Testing Market: Methodology and Scope
                    1.1. Market Segmentation and Scope
                        1.1.1. Segment Definitions
                            1.1.1.1. Type Segment
                            1.1.1.2. Test Type Segment
                            1.1.1.3. Sample Type segment
                            1.1.1.4. End Use Segment
                    1.2. Estimates and Forecast Timeline
                    1.3. Objectives
                        1.3.1. Objective - 1
                        1.3.2. Objective - 2
                        1.3.3. Objective - 3
                    1.4. Research Methodology
                    1.5. Information Procurement
                        1.5.1. Purchased Database
                        1.5.2. GVR’s Internal Database
                        1.5.3. Secondary Sources
                        1.5.4. Primary Research
                    1.6. Information or Data Analysis
                        1.6.1. Data Analysis Models
                    1.7. Market Formulation & Validation
                    1.8. Model Details
                        1.8.1. Commodity Flow Analysis
                    1.9. List of Secondary Sources
                    1.10. List of Abbreviations
Chapter 2. U.S. HSV Testing Market: Executive Summary
                    2.1. Market Snapshot
                    2.2. Type and Test Type Snapshot
                    2.3. Sample Type and End Use Snapshot
                    2.4. Competitive Landscape Snapshot
Chapter 3. HSV Testing Market Variables, Trends, & Scope
                    3.1. Market Segmentation and Scope
                    3.2. Market Lineage Outlook
                        3.2.1. Parent Market Outlook
                        3.2.2. Related/Ancillary Market Outlook
                    3.3. Market Dynamics
                    3.4. Market Drivers Analysis
                        3.4.1. Rising prevalence of HSV infections
                        3.4.2. Advancements in molecular and point-of-care testing technologies
                        3.4.3. Public health initiatives and routine STI screening programs
                    3.5. Market Restraint Analysis
                        3.5.1. Limited diagnostic accuracy of serological tests
                        3.5.2. Stigma and underreporting associated with HSV infections
                    3.6. Porter’s Five Forces Analysis
                    3.7. PESTLE Analysis
                    3.8. Pipeline Analysis
Chapter 4. U.S. HSV Testing Market: Type Estimates & Trend Analysis
                    4.1. U.S. HSV Testing Market: Type Movement Analysis
                    4.2. HSV-1/HSV-2 Combines
                        4.2.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.3. HSV-1
                        4.3.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
                    4.4. HSV-2
                        4.4.1. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. U.S. HSV Testing Market: Test Type Estimates & Trend Analysis
                    5.1. U.S. HSV Testing Market: Test Type Movement Analysis
                    5.2. Serological tests
                        5.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.3. Direct detection tests
                        5.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.3.2. PCR
                            5.3.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                        5.3.3. Viral culture
                            5.3.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    5.4. Point-of-care tests
                        5.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. U.S. HSV Testing Market: Sample Type Estimates & Trend Analysis
                    6.1. U.S. HSV Testing Market: Sample Type Movement Analysis
                    6.2. Blood
                        6.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.3. Swabs
                        6.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    6.4. Cerebrospinal fluid
                        6.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. U.S. HSV Testing Market: End Use Estimates & Trend Analysis
                    7.1. U.S. HSV Testing Market: End Use Movement Analysis
                    7.2. Hospitals
                        7.2.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.3. Diagnostic Laboratories
                        7.3.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.4. Clinics and sexual health centers
                        7.4.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
                    7.5. Home care / self-testing
                        7.5.1. Market Revenue Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
                    8.1. Company Categorization
                    8.2. Strategy Mapping
                        8.2.1. NEW PRODUCT LAUNCH
                        8.2.2. PARTNERSHIPS
                        8.2.3. ACQUISITION
                        8.2.4. COLLABORATION
                        8.2.5. FUNDING
                    8.3. Key Company Market Share Analysis, 2024
                    8.4. Company Heat Map Analysis
                    8.5. Company Profiles
                        8.5.1. F. Hoffmann-La Roche Ltd
                            8.5.1.1. Company Overview
                            8.5.1.2. Financial Performance
                            8.5.1.3. Product Benchmarking
                            8.5.1.4. Strategic Initiatives
                        8.5.2. Abbott
                            8.5.2.1. Company Overview
                            8.5.2.2. Financial Performance
                            8.5.2.3. Product Benchmarking
                            8.5.2.4. Strategic Initiatives
                        8.5.3. Thermo Fisher Scientific Inc.
                            8.5.3.1. Company Overview
                            8.5.3.2. Financial Performance
                            8.5.3.3. Product Benchmarking
                            8.5.3.4. Strategic Initiatives
                        8.5.4. BD
                            8.5.4.1. Company Overview
                            8.5.4.2. Financial Performance
                            8.5.4.3. Product Benchmarking
                            8.5.4.4. Strategic Initiatives
                        8.5.5. Bio-Rad Laboratories, Inc
                            8.5.5.1. Company Overview
                            8.5.5.2. Financial Performance
                            8.5.5.3. Product Benchmarking
                            8.5.5.4. Strategic Initiatives
                        8.5.6. BIOMÉRIEUX
                            8.5.6.1. Company Overview
                            8.5.6.2. Financial Performance
                            8.5.6.3. Product Benchmarking
                            8.5.6.4. Strategic Initiatives
                        8.5.7. DiaSorin S.p.A.
                            8.5.7.1. Company Overview
                            8.5.7.2. Financial Performance
                            8.5.7.3. Product Benchmarking
                            8.5.7.4. Strategic Initiatives
                        8.5.8. Hologic, Inc.
                            8.5.8.1. Company Overview
                            8.5.8.2. Financial Performance
                            8.5.8.3. Product Benchmarking
                            8.5.8.4. Strategic Initiatives
                        8.5.9. Cepheid
                            8.5.9.1. Company Overview
                            8.5.9.2. Financial Performance
                            8.5.9.3. Product Benchmarking
                            8.5.9.4. Strategic Initiatives
                        8.5.10. QuidelOrtho Corporation
                            8.5.10.1. Company Overview
                            8.5.10.2. Financial Performance
                            8.5.10.3. Product Benchmarking
                            8.5.10.4. Strategic Initiatives

List of Tables

Table 1 List of abbreviations
Table 2 U.S. HSV Testing market, by type, 2021 - 2033 (USD Million)
Table 3 U.S. HSV Testing market, by test type, 2021 - 2033 (USD Million)
Table 4 U.S. HSV Testing market, by sample type, 2021 - 2033 (USD Million)
Table 5 U.S. HSV Testing market, by end use, 2021 - 2033 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in the U.S.
Fig. 5 Market research approaches
Fig. 6 Value-chain-based sizing & forecasting
Fig. 7 QFD modeling for market share assessment
Fig. 8 Market formulation & validation
Fig. 9 U.S. HSV testing market: market outlook
Fig. 10 U.S. HSV testing competitive insights
Fig. 11 Parent market outlook
Fig. 12 Related/ancillary market outlook
Fig. 13 Penetration and growth prospect mapping
Fig. 14 Industry value chain analysis
Fig. 15 U.S. HSV testing market driver impact
Fig. 16 U.S. HSV testing market restraint impact
Fig. 17 U.S. HSV testing market strategic initiatives analysis
Fig. 18 U.S. HSV testing market Type outlook key takeaways
Fig. 19 U.S. HSV testing market: Type movement analysis
Fig. 20 HSV-1/HSV-2 Combines market estimates, 2021 - 2033 (USD Million)
Fig. 21 HSV-1 market estimates, 2021 - 2033 (USD Million)
Fig. 22 HSV-2 market estimates, 2021 - 2033 (USD Million)
Fig. 23 U.S. HSV testing market test type outlook key takeaways
Fig. 24 U.S. HSV testing market: test type movement analysis
Fig. 25 Serological tests market estimates, 2021 - 2033 (USD Million)
Fig. 26 Direct detection tests market estimates, 2021 - 2033 (USD Million)
Fig. 27 PCR market estimates, 2021 - 2033 (USD Million)
Fig. 28 Viral culture market estimates, 2021 - 2033 (USD Million)
Fig. 29 Point-of-care tests market estimates, 2021 - 2033 (USD Million)
Fig. 30 U.S. HSV testing market sample type outlook key takeaways
Fig. 31 U.S. HSV testing market: sample type movement analysis
Fig. 32 Blood market estimates, 2021 - 2033 (USD Million)
Fig. 33 Swabs market estimates, 2021 - 2033 (USD Million)
Fig. 34 Cerebrospinal fluid market estimates, 2021 - 2033 (USD Million)
Fig. 35 U.S. HSV testing market end use outlook key takeaways
Fig. 36 U.S. HSV testing market: end use movement analysis
Fig. 37 Hospitals market estimates, 2021 - 2033 (USD Million)
Fig. 38 Diagnostic laboratories market estimates, 2021 - 2033 (USD Million)
Fig. 39 Clinics and sexual health centers market estimates, 2021 - 2033 (USD Million)
Fig. 40 Home care / self-testing market estimates, 2021 - 2033 (USD Million)
Fig. 41 U.S. HSV testing market share and leading players
Fig. 42 U.S. market share and leading players
Fig. 43 U.S. SWOT
Fig. 44 U.S. market estimates and forecasts, 2021 - 2033
Fig. 45 Market share of key market players- U.S. HSV Testing market